PRO2TECT-CONVERSION – Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral AKB-6548 for the Maintenece Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (Protocol # AKB-6548-CI-0015)

Study Details

A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in subjects with NDD-CKD

Learn More NCT number

Principal Investigators

  • Eric Brown, MD
Maryanne Ducey, DC, RN at 203-358-8879